4.7 Article Proceedings Paper

National estimates of the prevalence of Alzheimer's disease in the United States

Journal

ALZHEIMERS & DEMENTIA
Volume 7, Issue 1, Pages 61-73

Publisher

ELSEVIER SCIENCE INC
DOI: 10.1016/j.jalz.2010.11.007

Keywords

Alzheimer's disease; Dementia; Cognitive impairment; Prevalence; Population-based; Projection; Probability sampling

Funding

  1. NATIONAL INSTITUTE ON AGING [N01AG012106, N01AG002107, U01AG016976, U01AG009740, R01AG027010, R01AG011101] Funding Source: NIH RePORTER
  2. NIA NIH HHS [R01AG027010, R01 AG011101, U01 AG009740-10, U01 AG016976-09, U01 AG016976, R01AG011101, N01AG12106, U01AG009740, R01 AG027010, R01 AG011101-09, R01 AG027010-01, N01AG02107, U01 AG009740, U01AG016976] Funding Source: Medline

Ask authors/readers for more resources

Several methods of estimating prevalence of dementia are presented in this article. For both Brookmeyer and the Chicago Health and Aging project (CHAP), the estimates of prevalence are derived statistically, forward calculating from incidence and survival figures. The choice of incidence rates on which to build the estimates may be critical. Brookmeyer used incidence rates from several published studies, whereas the CHAP investigators applied the incidence rates observed in their own cohort. The Aging, Demographics, and Memory Study (ADAMS) and the East Boston Senior Health Project (EBSHP) were sample surveys designed to ascertain the prevalence of Alzheimer's disease and dementia. ADAMS obtained direct estimates by relying on probability sampling nationwide. EBSHP relied on projection of localized prevalence estimates to the national population. The sampling techniques of ADAMS and EBSHP were rather similar, whereas their disease definitions were not. By contrast, EBSPH and CHAP have similar disease definitions internally, but use different calculation techniques, and yet arrive at similar prevalence estimates, which are considerably greater than those obtained by either Brookmeyer or ADAMS. Choice of disease definition may play the larger role in explaining differences in observed prevalence between these studies. (C) 2011 The Alzheimer's Association. All rights reserved.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.7
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available